Both endogenous and exogenous estrogen decrease pulmonary artery (PA) vasoconstriction. Whether these effects are mediated via estrogen receptor (ER)-alpha or ERbeta, and whether the contribution of ERs is stimulus-dependent, remains unknown. We hypothesized that administration of the selective ER-alpha agonist propylpyrazole triol (PPT) and/or the selective ER-beta agonist diarylpropiolnitrile (DPN) rapidly decreases PA rapidly (<20 min) decreased phenylephrine-induced vasoconstriction. This effect, as well as PPT's effects on endothelium-dependent vasorelaxation, were neutralized by L-NAME. In contrast, selective ER-beta activation (DPN, M) rapidly decreased phase II of hypoxic vasoconstriction (HPV). L-NAME eliminated this phenomenon. Lower PPT or DPN concentrations were less effective. We conclude that both, ER-alpha and ER-beta decrease PA vasoconstriction. The immediate onset of effect suggests a nongenomic mechanism. The contribution of specific ERs appears to be stimulus-specific, with ER-alpha primarily modulating phenylephrine-induced vasoconstriction, and ER-beta inhibiting HPV. NO inhibition eliminates these effects, suggesting a central role for NO in mediating the pulmonary vascular effects of both ER-alpha and ER-beta. 
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-5 M) and hypoxia (pO 2 35-45 mmHg) were determined.
Endothelium-dependent and -independent vasorelaxation were measured by generating dose- rapidly (<20 min) decreased phenylephrine-induced vasoconstriction. This effect, as well as PPT's effects on endothelium-dependent vasorelaxation, were neutralized by L-NAME. In contrast, selective ER-beta activation (DPN, 10 -5 M) rapidly decreased phase II of hypoxic vasoconstriction (HPV). L-NAME eliminated this phenomenon. Lower PPT or DPN concentrations were less effective. We conclude that both, ER-alpha and ER-beta decrease PA vasoconstriction. The immediate onset of effect suggests a nongenomic mechanism. The contribution of specific ERs appears to be stimulus-specific, with ER-alpha primarily modulating phenylephrine-induced vasoconstriction, and ER-beta inhibiting HPV. NO inhibition eliminates these effects, suggesting a central role for NO in mediating the pulmonary vascular effects of both ER-alpha and ER-beta.
INTRODUCTION
Female sex is increasingly recognized as a protective factor in patients suffering from trauma and sepsis (12, 16) . The critical role of sex hormones has recently been recognized. In particular, 17β-estradiol (E2) has been shown to improve outcomes in experimental traumahemorrhage and shock (13, 14, 41) , sepsis (5, 7, 12), myocardial ischemia/reperfusion (39, 40) and acute lung injury (30, 35, 42) . The protective effects of 17β-estradiol are mediated via estrogen-receptor (ER)-α and ER-β. The effects of these estrogen receptor subtypes are tissue and compartment specific. For example, ER-α decreases proinflammatory cytokine production by splenic macrophages and Kupffer cells after trauma-hemorrhage (33, 34). On the other hand, ER-β decreases inflammatory markers and mortality in shock-induced lung injury (5, 42).
In this context, the recently discovered nongenomic effects of estrogen have gained much attention (21). In contrast to the well-described genomic effects, which occur at a transcriptional level and which take hours to days to develop, nongenomic mechanisms use existing proteins and signaling pathways, therefore taking only seconds to minutes to mediate their effects.
Estrogens have also been shown to affect the pulmonary vasculature (18). In fact, both endogenous and exogenous estrogen decrease pulmonary artery (PA) vasoconstriction under normoxic as well as hypoxic conditions (8, 19) . We have recently demonstrated that exogenous 17β-estradiol acutely decreases PA vasoconstriction through a rapid and therefore most likely nongenomic mechanism (17).
However, it is unknown whether the acute pulmonary vascular effects of E2 are mediated by ER-α or ER-β. This is of importance, since a better mechanistic understanding of the pulmonary vascular effects of E2 may allow for future nonhormonal, targeted therapeutic interventions in pulmonary hypertension and acute lung injury. In addition, better insights into pulmonary vascular estrogen receptor signaling may improve our current understanding of why acute and chronic hypoxic pulmonary hypertension are less common and less pronounced in females, while idiopathic pulmonary arterial hypertension is more prevalent in the female population (18, 20, 27 ).
In the systemic vasculature, both ER-α and ER-β have been demonstrated to mediate the vasodilator effects of estrogen (26, 43). This effect is mediated by genomic as well as nongenomic mechanisms, some of which include increases in local nitric oxide (NO) release (28). While the exact roles of ER-α and ER-β in the systemic vasculature have not been entirely characterized, data regarding the pulmonary vasculature are sparse and conflicting (3, 4, 11). We therefore hypothesized that the administration of selective ER-α and/or ER-β agonists acutely decreases PA vasoconstriction induced by pharmacologic and hypoxic stimuli.
In addition, we hypothesized that selective ER agonists exert their effects through a nitric oxidedependent mechanism.
To test our hypotheses, we measured isometric force displacement in isolated PA rings from adult male Sprague-Dawley rats. Our objectives were 1) to determine whether the selective ER-α agonist propylpyrazole triol (PPT) rapidly decreases phenylephrine-and hypoxia-induced PA vasoconstriction, 2) to investigate whether the selective ER-β agonist diarylpropiolnitrile (DPN) rapidly decreases phenylephrine-and hypoxia-induced PA vasoconstriction, and 3) to measure whether the effects of PPT and DPN are attenuated in the presence of the nitric oxide synthase inhibitor N(omega)-nitro-l-arginine methyl ester (L-NAME). 
MATERIALS AND METHODS

Animals
Isolated pulmonary artery ring preparation
Rats were anesthetized with intraperitoneal injections of pentobarbital (150 mg/kg).
Median sternotomy was performed and the heart and lungs were removed en bloc and placed in modified Krebs-Henseleit (KH) solution at 4°C. Under a dissecting microscope, extralobar pulmonary artery (PA) branches were dissected out and cleared of surrounding tissue. The right and left main branches were cut into 2-to 3-mm wide rings and suspended on steel hooks connected to force transducers (ADInstruments, Colorado Springs, CO) for isometric force measurement. Care was taken during the entire process to avoid injury to the endothelium. PA rings were immersed in individual water-jacketed organ chambers containing modified KrebsHenseleit solution bubbled with 95% O 2 /5% CO 2 at 37°C. Force displacement was recorded using a PowerLab (ADInstruments) eight-channel data recorder on an Apple iMac PowerPC G4
Computer (Apple Computer, Cupertino, CA).
Experimental protocol and groups
Before starting experimental protocols, the PA rings were stretched to a predetermined optimal passive tension of 750 mg. The rings were allowed to equilibrate for 60 min, during which time the KH solution was changed every 15 min. Viability of PA rings was determined by measuring maximum contractile response to 8x10 -2 M of KCl. The dosage of KCl was determined to produce maximal contractile response in previous experiments. After KCl washout, the integrity of each PA endothelium was evaluated by dilation with acetylcholine (ACh, 10 -6 M) after phenylephrine (PE, 10 -6 M) precontraction. Rings demonstrating <200 mg contraction to PE were discarded. In endothelium-intact PA, rings demonstrating <50% vasorelaxation to ACh were discarded as well. After washout of ACh, PA rings were allowed to equilibrate. After having established viability and endothelial integrity, and following equilibration, PA rings were exposed to pharmacologically or hypoxia-induced vasoconstriction, 
Pharmacologic vasoconstriction
To investigate the rapid effects of selective ER-agonists on PE-induced vasoconstriction, ER-agonists were added to the organ bath 10 minutes prior to PE (10 -6 M). Dose-response curves for PPT and DPN (10 -9 M, 10 -6 M, 5x10 -5 M) were generated. To investigate whether the pulmonary vascular effects of the selective ER-agonists are mediated by a NO-dependent mechanism, separate vasoreactivity experiments were performed in the presence and absence of the nitric oxide synthase (NOS) inhibitor N(omega)-nitro-l-arginine methyl ester (L-NAME, 10 -4 M). L-NAME was added to the organ bath 30 min prior to the ER-agonist. L-NAME concentration and timing of administration were based on previous experiments (37). PA vasoreactivity was investigated by generating dose-response curves to PE (10 -8 M -10 -5 M).
The ER-agonist was added to the organ bath 10 min prior to PE. After PE-precontraction, endothelium-dependent and -independent vasorelaxation were measured by generating doseresponse curves to ACh (10 -8 M -10 -4 M) and sodium nitroprusside (SNP, 10 -9 M -10 -5 M), respectively, as described previously (38). Vasoreactivity experiments were terminated after the concentration of ACh or SNP, respectively.
Hypoxic pulmonary vasoconstriction
To measure the effect of hypoxia on PA rings, we gassed PE-precontracted PA rings with 95% N 2 /5% CO 2 for 60 min. This produced a pO 2 of 35-45 mm Hg in the organ bath, which
was measured with a blood-gas analyzer (Synthesis 20; Instrumentation Laboratory, Lexington, MA). Dose-response curves for PPT and DPN (10 -9 M, 10 -6 M, 5x10 -5 M) were generated. To investigate whether the vasoactive effects of ER-agonists are mediated by NO, additional experiments were performed in the presence and absence of L-NAME (10 -4 M). L-NAME was added to the organ bath 30 min prior to the ER-agonist. As described in previous experiments, hypoxia caused a biphasic PA vasoconstriction: an early contraction (occurring 2-3 min after exposure to hypoxia) followed by a transient vasorelaxation and a late phase II (occurring 10-15 min after hypoxia exposure) contraction ( Fig. 1 ). Due to its very brief and transient nature, phase I vasoconstriction was not measured. Maximum phase II vasoconstriction was measured as the difference between the highest and lowest force displacements during hypoxia and expressed as a percentage of maximum PE-precontraction. Maximum vasorelaxation was measured as the difference between PE-precontraction and the lowest force displacements during hypoxia and expressed as a percentage of maximum PE-precontraction. Hypoxia experiments were terminated after 60 min of hypoxia.
Chemicals and reagents
All 
Presentation of data and statistical analysis
Force displacement after stimulation PE is expressed as percent change from baseline tension of 750 mg. Force displacement during hypoxia is expressed as percent change from the amount of PE-precontraction. All reported values are expressed as means ± SE. Experimental groups (n=3-10/group) were compared by two-way analysis of variance (ANOVA) with post hoc Bonferroni test or student's t test (Prism 4; Graphpad Software, San Diego, CA). Differences at an alpha level of 0.05 (P < 0.05) were considered statistically significant.
RESULTS
ER-α agonist PPT rapidly decreases pharmacologically -induced vasoconstriction
The selective ER-α agonist PPT at a 10 -9 M or a 10 -6 M concentration did not 
ER-α agonist PPT rapidly decreases pharmacologically-induced vasoconstriction by a nitric oxide-dependent mechanism
To confirm the above described results, and to further investigate whether the observed PPT-related decrease in PE-induced vasoconstriction is mediated by a NO-dependent mechanism, we performed vasoreactivity studies by generating dose-response curves to PE.
After PE-precontraction, endothelium-dependent and -independent vasorelaxation were measured by generating dose-response curves to ACh and SNP, respectively. The PPT concentration found to be effective in the above described experiments (5x10 -5 M) was used for the vasoreactivity studies. PPT significantly decreased vasoconstriction at all PE concentrations (Fig. 3a) . However, in the presence of the non-selective NOS inhibitor L-NAME, this effect was significantly attenuated, indicating that PPT decreases PE-induced vasoconstriction by a NOdependent mechanism. The vasodilator effects of PPT in the presence of ACh were attenuated by L-NAME as well, again indicating that PPT exerts its vasodilator effects through NO (Fig. 3b) .
As expected, NOS-inhibition did not affect endothelium-independent vasorelaxation (Fig. 3c) .
ER-α agonist PPT and ER-β agonist DPN do not affect vasorelaxation during hypoxia
Both, PPT and DPN in the highest concentrations enhanced vasorelaxation during hypoxia similar to E2 (PPT: -130.90±12.73%, DPN: -100.55±7.84%, E2: -130.90±13.70%, control: -72.94±4.16%). However, this effect was not different from vehicle (-108.13±6.91%).
There were no significant differences in vasorelaxation between the highest concentrations of PPT and DPN, as well as E2 and vehicle when measuring maximum vasorelaxation (Fig. 4a) or individual time points during the vasodilatory phase of hypoxia ( Fig. 4b and c) .
ER-β agonist DPN rapidly decreases phase II hypoxic pulmonary vasoconstriction
PPT at 10 -6 M and 5x10 5a ). This effect was significantly more pronounced than the effects of PPT. In addition, the DPNinduced decrease in HPV was readily detectable 25 min after induction of hypoxia ( Fig. 5b and   5c ).
ER-β agonist DPN rapidly decreases phase II hypoxic pulmonary vasoconstriction by a nitric oxide-dependent mechanism
To investigate whether the DPN-related decrease of HPV is mediated by NO, HPV was examined in the presence of the NOS inhibitor L-NAME. Interestingly, the effects of DPN on phase II HPV were neutralized by L-NAME (78.87±25.31%), indicating that the DPN-related decrease in HPV is mediated by NO ( Fig. 6a and 6b ). In contrast, vasorelaxation during hypoxia was not affected by NO-inhibition (Fig. 7) .
DISCUSSION
Our data indicate that activation of ER-α or ER-β rapidly decreases pulmonary artery vasoconstriction. The selective ER-α agonist PPT rapidly attenuated phenylephrine-induced vasoconstriction, while the selective ER-β agonist DPN rapidly decreased phase II of acute HPV. These effects occurred within minutes of administration, suggesting a nongenomic mechanism. The observation that this decrease in PA vasoconstriction was attenuated by NOS-inhibition indicates that the pulmonary vascular effects of ER-α and ER-β are mediated by a NO-dependent mechanism. These data are in concordance with previous cell culture data demonstrating that both estrogen receptors can rapidly activate eNOS (3, 4, 11). The novelty of our results is the finding that the contribution of specific estrogen receptors appears to be stimulus-specific, with ER-α primarily modulating phenylephrine-induced vasoconstriction, and ER-β mediating the inhibitory effect on acute HPV. To our knowledge, the effects of selective estrogen receptors on acute HPV have not been investigated yet.
Our findings of ER-α and ER-β mediating their effect by a NO-dependent mechanism provide a physiologic mechanism for the previously reported rapid vasodilator effects of E2 (8, 17). These rapid vasodilator effects of E2 were reproduced in the current study. As described and discussed in our previous paper (17), as well as by English et al. (8), E2 exerted its effects in isolated PA rings only at relatively high concentrations which may be difficult to achieve in vivo. In contrast, PPT and DPN exerted their vasoactive effects at 10-fold lower concentrations than E2, making these compounds a more feasible therapeutic option. A possible explanation for these findings is that only a small amount of E2 may interact with ER-α and ER-β to evoke acute, nongenomic effects, while a substantial amount of E2 may bind to cytosolic estrogen receptors and diffuse into the nucleus to exert slower, genomic effects. Alternatively, it is possible that PPT and DPN have higher affinities for estrogen receptors than E2 itself. In this context, it is of interest to note that PPT has a 410-fold higher binding affinity for ER-α than ER-β, while DPN has a 70-fold higher affinity for ER-β over ER-α (23, 31). The rapid onset of the ER-α and ER-β mediated decrease in PA vasoconstriction (<20 min for phenylephrine-induced vasoconstriction and <45 min for hypoxic vasoconstriction) is suggestive of a nongenomic increase in NO release. The concentrations required to mediate these effects were similar to those reported by other investigators demonstrating vasorelaxation in isolated systemic arteries (6, 36). response that characterizes these conditions (1, 22, 44) . Along these lines, our laboratory has
recently been able to demonstrate that estradiol-treated mesenchymal stem cells improve myocardial recovery after global ischemia in an isolated heart model (9). Whether ER-α and ER-β are capable of decreasing the inflammatory response and remodeling within the vessel wall that are associated with hypoxic pulmonary hypertension as well as idiopathic pulmonary arterial hypertension (iPAH) (15, 32) , will need to be explored in future experiments.
Further insights into sex hormone receptor pathways may also improve the current knowledge of why acute and chronic hypoxic pulmonary hypertension are less common in females (18, 20, 27), while iPAH, a disabling condition characterized by PA vasoconstriction and remodeling as well as in-situ thrombosis and eventually right heart failure, occurs twice as frequently in the female population (20). Furthermore, oral contraceptives have been considered to be a potential risk factor for iPAH (20). It is conceivable that a defect in estrogen-receptor pathways or intracellular signaling may contribute to these disparate findings. In this context, it is interesting to note that ER-α activation attenuated hypoxia-induced vasoconstriction, while ER-β activation decreased PA vasoconstriction induced by a non-hypoxic stimulus. This raises the question whether the previously described sex differences in hypoxic pulmonary hypertension and iPAH may at least in part be due to differences in ER-α and/or ER-β signaling.
PERSPECTIVES AND SIGNIFICANCE
Selective estrogen receptor agonists could provide a promising new strategy to further explore the role of sex differences and the roles of ER-α and ER-β in animal models of pulmonary hypertension. The findings of the present study advance the current knowledge of the pulmonary vascular effects of estrogen by demonstrating that both, ER-α and ER-β decrease vasoconstriction in a model of isolated pulmonary artery rings in a rapid and therefore most likely nongenomic manner. The contribution of specific ERs appears to be stimulus-specific, with ER-α primarily modulating phenylephrine-induced vasoconstriction, and ER-β inhibiting acute hypoxic pulmonary vasoconstriction. The observation that NOS inhibition eliminates these effects suggests a central role for NO in mediating the rapid pulmonary vascular effects of both ER-α and ER-β. Since L-NAME is a nonspecific NOS inhibitor, the current study does not allow any conclusions as to which specific NOS isoform is mediating the vasorelaxatory effects of selective estrogen receptor agonists. However, data from the systemic vasculature and from experiments with isolated pulmonary artery endothelial cells suggest that eNOS most likely represents the responsible isoform. In future experiments, we will try to identify which NOS isoform is responsible for the ER-α and ER-β induced generation of NO observed in our model. Current research efforts in our laboratory aim to identify the mediators of ER-induced pulmonary vasorelaxation that act both upstream and downstream of NO, as this represents an area which holds promise to identify potential future therapeutic targets. Finally, the use of ER-α and ER-β specific antagonists in the presence and absence of PPT and DPN may allow for further characterization of the roles of ER-α and ER-β in the pulmonary vasculature.
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DISCLOSURES
None. Vasoreactivity studies for PPT with and without NOS-inhibition using L-NAME. PPT was added to the organ bath 10 min prior to PE. L-NAME was added 40 min prior to PE. Force in fig. 3a is expressed as percent change from baseline, while force in fig. 3b and 3c is expressed as change from PE-precontraction. PPT rapidly and significantly decreased PEmediated vasoconstriction. This effect was attenuated in the presence of L-NAME (A). L-NAME also attenuated PPT vasodilator effects in the presence of ACh (B). In contrast, endotheliumindependent vasorelaxation was not affected by NOS-inhibition (C). N=3-7/group. † p<0.05 vs. vehicle; † † p<0.001 vs. vehicle; * p<0.001 vs. PPT + L-NAME; # p<0.001 vs. L-NAME; ‡ p<0.05 vs. PPT + L-NAME. 
